# A GLP-1 Self-Experiment: What the Biomarkers Actually Revealed
One journalist decided to test what millions of people are now taking GLP-1 receptor agonists to achieve. Instead of relying on anecdotes or celebrity endorsements, he measured what matters: the biological markers that predict disease risk and longevity.
GLP-1 drugs like semaglutide and tirzepatide were originally developed for type 2 diabetes. They work by slowing gastric emptying, reducing appetite, and improving insulin sensitivity. Pharmaceutical companies market them as weight-loss agents. Social media markets them as transformation tools. The question this writer asked was simpler: what do the numbers actually show?
The experiment tracked biomarkers before and after GLP-1 use. These included fasting glucose, insulin levels, lipid panels, liver enzymes, kidney function, and inflammatory markers. The results proved predictable for someone without metabolic disease. Weight dropped modestly. Waist circumference decreased. Fasting glucose improved, though it was already in the normal range. Triglycerides declined. LDL cholesterol fell slightly. The inflammatory marker C-reactive protein remained stable.
This matters because it exposes a gap between objective improvement and subjective experience. The biomarkers signaled better metabolic health. The body looked different. But the person felt largely the same.
That disconnect matters for how people understand these drugs. A 30-year-old with normal blood sugar does not get sick from high blood sugar. He has zero diabetes risk. Yet GLP-1s were still reducing his fasting glucose. The drugs work mechanically, independent of baseline disease. They optimize a system that was already functioning.
The real question becomes whether optimizing an already-healthy metabolic system produces real-world benefit. The research community has not finished answering this. Studies on lean or normal-weight people taking GLP-1s remain sparse. Long-term safety data in non-diabetic populations barely exists. We know these drugs reduce cardiovascular events in people with type 2 diabetes and obesity. We do not know if they prevent events in metabolically healthy people who take them purely for weight.
This creates a practical dilemma for the estimated 3 million Americans currently using GLP-1s off-label for weight loss. They inherit the side-effect profile of a diabetes drug without certainty that the drug addresses their actual disease. Nausea, vomiting, constipation, and pancreatitis reports continue to mount. Muscle loss occurs alongside fat loss. Appetite returns after stopping the drug.
The writer's conclusion bridges the gap between biomarkers and lived experience. Better blood work does not automatically translate to feeling better or living longer, especially when starting from a baseline of health. The numbers improved because the drug works as designed. But numbers alone do not justify long-term use in someone without metabolic disease.
For the GLP-1 boom to mature beyond hype, users need honest conversations about risk-benefit ratios when baseline risk is already low. The biomarkers tell one story. Your actual health status tells another.